The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting

The story of GLP-1 drugs keeps getting bigger. First they transformed the treatment of diabetes. Then they upended the ...

Weight-loss drugs may cut breast cancer risk by up to 30%, study finds

Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study. View on euronews ...

Women on GLP-1 drugs 30 percent less likely to develop breast cancer

Women taking GLP-1 drugs 30 percent less likely to develop breast cancer, researchers say - About 42,140 women are expected ...
Science Daily

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were ...
Science Daily

One fat helped pancreatic cancer grow while another cut disease in half

A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how ...

A single clonal starting point may explain how multiple cervical cancer subtypes arise

How do different cancer subtypes arise? Do they originate from distinct cells, or from a single multipotent cell capable of ...

Early Research Suggests a Path to Predict and Prevent Lung Cancer

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...

AI finds signs of pancreatic cancer before tumors develop

An artificial intelligence model from the Mayo Clinic detected early signs of possible pancreatic cancer on scans up to two years before patients were diagnosed.

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring ...